01—Abstract
Summary
Summary of the 8-K filed February 20, 2025. Cited figures are marked; the original filing is the authoritative source.
Insmed Incorporated reported fourth-quarter and full-year 2024 financial results on February 20, 2025, per a press release furnished as Exhibit 99.1.
Total ARIKAYCE revenue was $104.4 milliona for the fourth quarter and $363.7 million for the full year 2024, a 19.2% increase over 2023, exceeding the upper end of full-year 2024 guidance. The company reiterated full-year 2025 global ARIKAYCE revenue guidance of $405 million to $425 million. Net loss was $235.5 million ($1.32 per share) for the fourth quarter and $913.8 million ($5.57 per share) for the full year 2024.
Cash, cash equivalents, and marketable securities totaled approximately $1.4 billionb at December 31, 2024. The most significant pipeline development is the FDA's acceptance of the brensocatib New Drug Application for bronchiectasis with Priority Review and a PDUFA target action date of August 12, 2025. The company expects a U.S. launch in the third quarter of 2025 if approved.
Topline data timing was reiterated for TPIP in PAH (mid-2025), brensocatib in CRSsNP (end of 2025), and ENCORE for ARIKAYCE (first quarter of 2026). The company also plans a Phase 3 study of TPIP in PH-ILD in the second half of 2025 and initiation of a clinical study of gene therapy INS1201 in the first half of 2025.
In a separate Item 5.02 disclosure, director Alfred Altomari notified the Board on February 18, 2025 that he will not stand for re-election at the 2025 Annual Meeting of Shareholders. He will continue serving on the Board and its Audit and Compensation Committees until then, and the filing states his decision was not due to any disagreement with the company.
02—Key points
Key Highlights
- ARIKAYCE full-year 2024 revenue of $363.7 million, up 19.2% from $305.2 million in 2023, above the upper end of the full-year 2024 guidance range
- Fourth-quarter 2024 ARIKAYCE revenue of $104.4 million, compared with $83.7 million in the fourth quarter of 2023
- 2025 global ARIKAYCE revenue guidance of $405 million to $425 million, reiterated
- FDA accepted the brensocatib NDA for bronchiectasis with Priority Review; PDUFA target action date of August 12, 2025
- Full-year 2024 net loss of $913.8 million ($5.57 per share), versus $749.6 million ($5.34 per share) in 2023, with SG&A rising to $461.1 million from $344.5 million
- Cash, cash equivalents, and marketable securities of approximately $1.4 billion at December 31, 2024
- Director Alfred Altomari will not stand for re-election at the 2025 Annual Meeting; decision not related to any disagreement with the company
03—Questions
Frequently Asked Questions
When could brensocatib reach the U.S. market, and what is the regulatory timeline?
The FDA accepted the brensocatib NDA for bronchiectasis and granted Priority Review with a PDUFA target action date of August 12, 2025. Insmed continues to expect a U.S. launch in the third quarter of 2025 if approved. Regulatory submissions in the EU, UK, and Japan are planned for 2025, with commercial launches anticipated in 2026, pending approval in each territory.
What drove the increase in operating expenses in 2024?
R&D expenses rose to $598.4 million in 2024 from $571.0 million in 2023, and SG&A rose to $461.1 million from $344.5 million. The filing attributes these increases primarily to compensation, benefit-related and stock-based compensation expenses from higher headcount, with SG&A growth also tied to preparation for the anticipated brensocatib launch.
What is the company's expected ARIKAYCE revenue for 2025?
Insmed reiterated full-year 2025 global ARIKAYCE revenue guidance of $405 million to $425 million, which the filing states represents between 11% and 17% year-over-year growth compared to 2024.
What are the key clinical catalysts and timing disclosed in this filing?
The company expects topline data from the Phase 2b TPIP study in PAH in mid-2025, topline results from the Phase 2b BiRCh study of brensocatib in CRSsNP by the end of 2025, and topline results from the Phase 3 ENCORE study of ARIKAYCE in the first quarter of 2026.
Is the board departure of Alfred Altomari related to any company issue?
No. The filing states that Mr. Altomari's decision not to stand for re-election was not a result of any disagreement with the company on any matter relating to its operations, policies or practices. He will continue on the Board and its Audit and Compensation Committees until the 2025 Annual Meeting.
04—Continue